Treatment of severe aplastic anaemia with combined immunosuppression: anti‐thymocyte globulin, ciclosporin and mycophenolate mofetil
Open Access
- 16 May 2006
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 133 (6) , 606-611
Abstract
Summary: Severe aplastic anaemia (SAA) can be successfully treated with immunosuppressive therapies or haematopoietic stem cell transplantation (HSCT). Response rates with horse anti‐thymocyte globulin (h‐ATG) plus ciclosporin (CsA) are about 60–70%, and robust responders have an excellent long‐term survival. We introduced a third immunosuppressive agent to standard h‐ATG/CsA, mycophenolate mofetil (MMF), in an attempt to improve the response rate and survival, and to decrease the relapse rate and clonal evolution to myelodysplasia. A total of 104 consecutive patients with SAA were treated with h‐ATG/CsA/MMF between May 1999 and June 2003 at the National Institutes of Health Clinical Center. The overall response rate at 6 months was 62%, with 24 (37% of responders) patients relapsing at a median of 389 d from ATG. Nine patients showed evidence of clonal evolution following ATG. After a median follow up of 42 months, the median survival among responders was not reached and among non‐responders was 58 months. Over half of the relapses occurred during MMF administration. Despite a strong theoretical rationale for its use, MMF did not result in the improvement of response or relapse rates when compared with historical standard h‐ATG/CsA.Keywords
This publication has 23 references indexed in Scilit:
- Induction of Islet Allotolerance in Nonhuman PrimatesAnnals of the New York Academy of Sciences, 2006
- Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus NephritisNew England Journal of Medicine, 2005
- Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant RecipientsThe Journal of Heart and Lung Transplantation, 2005
- Cyclosporine A and Mycophenolate Mofetil vs Cyclosporine A and Methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblingsBone Marrow Transplantation, 2005
- Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathyRheumatology, 2004
- Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantationBone Marrow Transplantation, 2004
- Treatment of acquired severe aplastic anemia: Bone marrow transplantation compared with immunosuppressive therapy-the European group for blood and marrow transplantation experienceSeminars in Hematology, 2000
- Immunosuppressive treatment of aplastic anemia with antithymocyte globulin and cyclosporineSeminars in Hematology, 2000
- A BLINDED, LONG-TERM, RANDOMIZED MULTICENTER STUDY OF MYCOPHENOLATE MOFETIL IN CADAVERIC RENAL TRANSPLANTATIONTransplantation, 1998
- Treatment of Aplastic Anemia with Antilymphocyte Globulin and Methylprednisolone with or without CyclosporineNew England Journal of Medicine, 1991